12. (Original) The kit of claim 11, wherein the *Leishmania* parasite is *L. tropica, L. mexicana, L. guyanensis, L. braziliensis, L. major, L. donovani, L. chagasi, L. amazonensis, L. peruviana, L. panamensis, L. pifanoi, L. infantum,* or *L. aethiopica.*

13-17. (Canceled).

18. (Original) A vaccine comprising the microfluidized lysate preparation of claim 4.

19–21. (Canceled).

22. (Original) A pharmaceutical composition comprising the microfluidized lysate preparation of claim 4 and a pharmaceutically acceptable stabilizer.

23. (Original) The pharmaceutical composition of claim 22, wherein the pharmaceutically acceptable stabilizer is phenol.

24. (Original) The pharmaceutical composition of claim 22, wherein the composition is in the form of a liquid.

25. (Original) The pharmaceutical composition of claim 22, wherein the composition may be frozen or freeze-dried.

26-28. (Canceled).

29. (New) The microfluidized lysate preparation of claim 4, wherein the microfluidized lysate preparation is heat treated.

30. (New) The microfluidized lysate preparation of claim 4, wherein the *Leishmania* parasite is *L. tropica, L. mexicana, L. guyanensis, L. braziliensis, L. major, L. donovani, L. chagasi, L. amazonensis, L. peruviana, L. panamensis, L. pifanoi, L. infantum,* or *L. aethiopica.*